Liminatus Pharma (LIMN) Profit After Tax (2024 - 2026)

Liminatus Pharma has reported Profit After Tax for 3 years, with the latest figure at -$1.1 million in Q1 2026.

• Quarterly Profit After Tax fell 243.09% year-over-year to -$1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.0 million (down 419.03% YoY) and the FY2025 annual result came in at -$10.2 million, down 187.81% from the prior year.
• Profit After Tax improved to -$1.1 million in Q1 2026 per LIMN's latest filing, from -$8.2 million in the prior quarter.
• Over five years, Profit After Tax peaked at $113287.0 in Q2 2025 and troughed at -$8.2 million in Q4 2025.
• A 3-year average of -$1.6 million and a median of -$781289.5 in 2024 frame the typical range for Profit After Tax.
• The widest YoY moves for Profit After Tax: up 111.79% in 2025, down 3455.54% in 2025.
• Over 3 years, Profit After Tax stood at -$229752.0 in 2024, then sank by 3455.54% to -$8.2 million in 2025, then surged by 86.24% to -$1.1 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$1.1 million, -$8.2 million, and -$1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.